Advertisement
For patients with advanced unresectable hepatocellular carcinoma

Sorafenib Effect on HCC Survival Depends on Hepatitis Status

0
Findings in meta-analysis of individual patient data for advanced unresectable hepatocellular carcinoma
Chemotherapy that's been delayed due to slow recovery from non-small-cell lung cancer surgical resection can still provide real benefit to patients

Delayed Chemo After Surgery Still Beneficial in Lung Cancer

0
Patient recovery may mean longer time to chemotherapy, but treatment can still have benefit
From 2000 to 2011 there were shifts in the treatment of advanced-stage non-small-cell lung cancer

2000 to 2011 Saw Shift in Treatment for Advanced NSCLC

0
Rise in use of pemetrexed, erlotinib, bevacizumab; longest treatment duration with these agents
An artificial larynx has provided long-term relief for a throat cancer patient in France who had a total laryngectomy

Artificial Larynx Implant Feasible After Total Laryngectomy

0
New device has improved long-term quality of life in patient with total laryngectomy
Diagnostic laparoscopy reduces the number of futile laparotomies in women with suspected advanced-stage ovarian cancer

Laparoscopy Can Prevent Futile Primary Cytoreductive Surgery

0
Findings in women with suspected advanced-stage ovarian cancer
Cancer mortality rates in the United States have dropped 25 percent since the early 1990s

Cancer Mortality Rates Continue to Decline in the United States

0
Researchers credit declines in smoking, better detection and treatment
Patients with sustained or newly developed cancer cachexia at six and 12 months after initial treatment for advanced head and neck squamous cell carcinoma are at higher risk of cancer recurrences

Cancer Cachexia Associated With Poor Outcomes

0
Findings at six and 12 months after treatment for advanced head and neck cancer
The interface between allergic responses and oncology is being explored

Interface Between Allergy, Oncology Explored

0
Position paper focuses on interface between allergic responses and cancer, immunotherapy
Compared with non-cancer controls

More Cognitive Difficulties for Patients After Chemotherapy

0
Breast cancer survivors report cognitive issues after chemo, through six-month follow-up
Use of zoledronic acid every 12 weeks does not result in increased risk of skeletal events compared with use every four weeks among patients with bone metastases due to breast cancer

Zoledronic Acid Every 12 Weeks Noninferior in Bone Metastases

0
No increase in risk of skeletal events versus treatment every four weeks for bone metastases